RxDoctor Payments Data

Maria Ramirez

Family · Wilson, NCNPI 1801540562

Payments from drug & device makers

$2,434in general payments, 2019–2025

Across 111 payments — averaging $21.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$577
  • AbbVie$300
  • GSK$288
  • United Therapeutics Corporation$179
  • Novo Nordisk$165
  • Harmony Biosciences LLC$152
  • plus $773 from 22 others

What the payments were for

  • Food & beverage$2,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,434 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,897
Medicare patients
41
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$97,372
JardianceEmpagliflozin60$63,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$42,275
FarxigaDapagliflozin Propanediol34$32,744
MounjaroTirzepatide15$16,354
EliquisApixaban15$15,824
Repatha SureclickEvolocumab14$11,317
TrulicityDulaglutide11$10,825
SymbicortBudesonide/Formoterol Fumarate22$6,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,026
Albuterol Sulfate HfaAlbuterol Sulfate76$1,406
Gabapentin73$1,359
Atorvastatin Calcium112$997
Montelukast Sodium80$942
Omeprazole81$916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$165$97,37270 claims
Boehringer IngelheimJardiance$58$63,75360 claims
GSKTrelegy Ellipta$288$42,27558 claims
AstraZenecaFarxiga, Symbicort$577$39,43256 claims
Lilly USA, LLCMounjaro, Trulicity$105$27,17926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.

Other family in Wilson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →